Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clinical study of switching from intravenous (IV) to subcutaneous (SC) infliximab patients with inflammatory bowel disease

Next Previous
Trial Profile

Clinical study of switching from intravenous (IV) to subcutaneous (SC) infliximab patients with inflammatory bowel disease

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 02 May 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Infliximab (Primary) ; Infliximab (Primary)
  • Indications Crohn's disease; Inflammatory bowel diseases; Ulcerative colitis
  • Focus Therapeutic Use
  • Acronyms REMSWITCH; Remswitch-Lt

Most Recent Events

  • 21 Apr 2026 According to a Celltrion media release, data from this trial will be presented at the 2026 Digestive Disease Week (DDW) Annual Meeting, taking place May 2-5 in Chicago, Illinois.
  • 30 Nov 2023 Results reporting long-term efficacy and safety data after a median follow-up of 18 months published in the Alimentary Pharmacology and Therapeutics
  • 17 Oct 2023 Results assessing the long-term effectiveness and acceptability of switching from intravenous to subcutaneous infliximab in patients with inflammatory bowel diseases (IBDs) treated with or without intensi-fied intravenous regimen, presented at the 31st United European Gastroenterology Week.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top